Reckitt Benckiser Group Plc: Buy, Sell Or Hold?

What are the long-term prospects for Reckitt Benckiser Group plc (LON: RB)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always searching for shares that can help ordinary investors like you make money from the stock market.

Right now I am trawling through the FTSE 100 (UKX) and giving my verdict on every member of the blue-chip index.

I hope to pinpoint the very best buying opportunities in today’s uncertain market, as well as highlight those shares I feel you should hold… and those I feel you should sell!

I’m assessing every share on five different measures. Here’s what I’m looking for in each company:

1. Financial strength: low levels of debt and other liabilities;

2. Profitability: consistent earnings and high profit margins; 

3. Management: competent executives creating shareholder value;

4. Long-term prospects: a solid competitive position and respectable growth prospects, and;

5. Valuation: an under-rated share price.

A look at Reckitt Benckiser

Today I’m evaluating Reckitt Benckiser (LSE: RB) (NASDAQOTH: RBGLY.US), a British multinational consumer goods company that manufactures household cleaning, and health and personal care products,which currently trades at 4,670p. Here are my thoughts:

1. Financial strength: Reckitt Benckiser is in solid financial health. Net debt/EBITDA ratio is less than 1 and interest cover is a hefty 171 times. Also, during the past 10 years, the company has converted an average of 18% of its revenue into free cash flow (FCF) and delivered over £1bn in FCF per year.

2. Profitability: Reckitt Benckiser has been one of the best-performing companies in the FTSE 100 index over the past decade. The company has grown revenue per share more than 2.5 times, operating profit per share and adjusted earnings per share more than 3.5 times, and dividend per share almost 5 times. Operating margin has consistently averaged an industry leading 23% and return on equity (ROE) has been stellar, averaging 35% per year.

3. Management: Bart Becht was the company’s CEO from 1999 to 2011. Under his tenure, the company achieved great success with its focus on marketing its core brands and excellent product innovation, value-enhancing acquisitions, and improved supply chain efficiency. His replacement, Rakesh Kapoor, has been with the company since 1987 serving various roles.     

4. Long-term prospects: Reckitt Benckiser is the world leading maker of household cleaning products and also owns a strong portfolio of brands in health and personal care. Its core products — which the company refers to as ‘Powerbrands’ — include household names like Durex, Strepsils, Dettol, Woolite and Clearasil.

Recently, the company laid out plans on focusing more on high growth and high margin product categories and regions. These include concentrating its efforts and capital spending on its health and hygiene business and into developing markets. The company is targeting to grow the proportion of revenue derived from health and hygiene products and faster growing regions to 50% and 72% of group revenue by 2015, respectively. At the end of 2012 they represented 44% and 68% of group revenue.   

Also, late last year, the company acquired Schiff Nutrition, a leading provider of vitamins and supplements in the US. The company sees this as a platform to launch its entry into the large and growing global vitamins and supplements market.

Furthermore, the company’s pharmaceutical business continues to be highly profitable increasing its net revenue by 10% and operating profit by 3% in 2012 despite its high-selling Suboxone tablets losing patent protection in 2010. Since then, the company has successfully transitioned to Suboxone‘s film version which is patent protected until 2020.

However, the future profitability of its pharmaceutical business still remains a concern with the lingering threat of generic competition, government regulation, and healthcare reform.  

5. Valuation: Reckitt Benckiser shares are trading at a forward P/E of 17, slightly lower than its 10-year P/E average of 18, and at 30 times its 10-year average earnings. Also, it returns a dividend yield of 3%, twice covered.

My verdict on Reckitt Benckiser

If you were fortunate enough to hold on to Reckitt Benckiser shares for over a decade –you would have been rewarded with annualised returns of 17% per year. Reckitt Benckiser is one of those Buffet-type shares –companies that are well-run, have strong brands, earn great returns on capital and generate robust free cash flows. However, the problem with these kinds of companies is that they rarely trade at a discount which lowers your margin of safety.

On the other hand, you could also say Reckitt Benckiser shares were trading at the same heady valuations 10 years ago. So, it would not be unreasonable to assume that it can deliver returns close to what it achieved last decade; its fundamentals remain intact and its future looks promising.

Still, even though it is a ‘wonderful’ company, I do not think it has a wide enough economic moat that would make me comfortable buying it at these prices. Plus, there are other similar companies you could get for a lower price.           

So overall, I believe Reckitt Benckiser at 4,670p looks like a hold.

More FTSE opportunities

Although I feel Reckitt Benckisale is a hold right now, I am more positive on the FTSE shares highlighted in “8 Dividend Plays Held By Britain’s Super Investor“. This exclusive report reveals the favourite income stocks owned by Neil Woodford — the City legend whose High Income fund turned £10,000 into £193,000 during the 25 years to 2012.

The report, which explains the full investing logic behind Mr Woodford’s dividend strategy and his preferred blue chips, is free to all private investors. Just click here for your copy. But do hurry, as the report is available for a limited time only.

In the meantime, please stay tuned for my next verdict on a FTSE 100 share.

> Zarr does not own any share mentioned in this article.

More on Investing Articles

Investing Articles

Nvidia stock is up 30% in 2025 – can it repeat the rally in 2026?

As the poster child of the AI revolution, Nvidia gets a closer look from Andrew Mackie -- can the stock…

Read more »

Investing Articles

Should I sell my HSBC shares in 2026?

HSBC shares have produced market-thumping returns in 2025. So what should I do with this FTSE 100 bank stock in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 2 UK shares were stinking out my SIPP – now they’re flying! What next?

Harvey Jones has been given a very bumpy ride by these two UK shares. But now they're looking up and…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I’ve just added this under-the-radar FTSE 100 stock to my SIPP

James Beard explains why he’s put this relatively unknown share in his Self-Invested Personal Pension (SIPP). And so far, he…

Read more »

Investing Articles

How much do you need in a Stocks and Shares ISA to target £1,500 a month in passive income?

This writer shares how he’s working to turn his Stocks and Shares ISA into a source of passive income, harnessing…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Will Rolls-Royce shares be the gift that keeps on giving in 2026?

It's been another superb year for anyone holding Rolls-Royce shares. But Paul Summers wonders if a hefty price tag will…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£5,000 invested in Glencore shares in January 2025 is now worth…

I’m building my 2026 ISA and Glencore shares keep pulling me back. One chart shows why the miner’s earnings mix…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

How much do you actually need in an ISA to target £2,500 per month in passive income?

Dr James Fox believes all Britons should be using their Stocks and Shares ISAs if they have to means to…

Read more »